# Cardiac Safety of Lansoprazole and Domperidon Combination

> **NCT03355170** · PHASE4 · WITHDRAWN · sponsor: **Neutec Ar-Ge San ve Tic A.Ş**

## Conditions studied

- GERD
- Cardiac Event
- Safety Issues

## Interventions

- **COMBINATION_PRODUCT:** Lansoprazole/Domperidone
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT03355170
- **Lead sponsor:** Neutec Ar-Ge San ve Tic A.Ş
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-01
- **Primary completion:** 2018-12-01
- **Final completion:** 2019-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor decided to continue with a different design and a different protocol.
- **Last updated:** 2023-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03355170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03355170, "Cardiac Safety of Lansoprazole and Domperidon Combination". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03355170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*